ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. CLSD, a biopharmaceutical firm revolutionizing the supply of therapies to the again of the attention by way of the suprachoroidal area (SCS®), introduced at this time that Anthony S. Gibney has been appointed to the Firm’s Board of Administrators, efficient April 15, 2024.
“We’re delighted to welcome Tony to our Board of Administrators as we construct on our management in delivering therapeutics to the suprachoroidal area,” mentioned Clay Thorp, Chair of the Clearside Board of Administrators. “We consider Tony’s important expertise driving worth for biotech firms by way of profitable pipeline improvement, financing, partnering and M&A can be a useful useful resource to the Clearside workforce as we enter this pivotal progress part of the corporate.”
George Lasezkay, Pharm.D., J.D., President and Chief Government Officer of Clearside, commented, “Tony’s deep understanding of the biotech enterprise, mixed along with his current and related expertise at Iveric Bio, will present vital perception and steering for our strategic and enterprise improvement initiatives as we glance in direction of a possible Section 3 program for our lead medical program, CLS-AX in moist AMD, and discover alternatives for suprachoroidal pipeline enlargement.”
“I’m honored to affix the Board of Administrators as Clearside provides a differentiated strategy within the ophthalmology area,” mentioned Mr. Gibney. “I look ahead to partnering with the management workforce and Board to generate worth based mostly on the chance for CLS-AX in retinal illnesses and Clearside’s revolutionary suprachoroidal supply platform that I consider has broad potential to enhance outcomes for people residing with quite a few sight-threatening illnesses.”
Anthony S. Gibney is an skilled biotechnology government and former funding banker who brings over 25 years of expertise devoted to advising biotechnology firms within the U.S. and Europe on enterprise technique, collaboration transactions, financings, and mergers and acquisitions. Most just lately, Mr. Gibney served because the Government Vice President, Chief Enterprise & Technique officer of Iveric Bio, Inc. till the corporate’s acquisition by Astellas Pharma Inc. in July 2023. Previous to that, Mr. Gibney served as Chief Monetary Officer and Chief Enterprise Officer at Fog Prescription drugs, Inc., the place he oversaw its enterprise improvement, technique and finance capabilities, and he served as Government Vice President and Chief Enterprise Officer at Achillion Prescription drugs, the place he led the sale of Achillion to Alexion Prescription drugs, Inc. in 2020. Earlier than Achillion, Mr. Gibney was a Managing Director and Co-head of the biotechnology funding banking workforce at Leerink Companions LLC, and Managing Director of Merrill Lynch’s healthcare group. He at present serves on the boards of administrators of LAPIX Therapeutics, Inc. and InflaRx N.V. Mr. Gibney acquired a B.A. in Economics and a B.A. in Historical past from Yale College.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical firm revolutionizing the supply of therapies to the again of the attention by way of the suprachoroidal area (SCS®). Clearside’s SCS injection platform, using the Firm’s patented SCS Microinjector®, allows an in-office, repeatable, non-surgical process for the focused and compartmentalized supply of all kinds of therapies to the macula, retina, or choroid to probably protect and enhance imaginative and prescient in sufferers with sight-threatening eye illnesses. Clearside is growing its personal pipeline of small molecule product candidates for administration through its SCS Microinjector. The Firm’s lead program, CLS-AX (axitinib injectable suspension), for the remedy of neovascular age-related macular degeneration (moist AMD), is in Section 2b medical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is offered within the U.S. by way of a business accomplice. Clearside additionally strategically companions its SCS injection platform with firms using different ophthalmic therapeutic improvements. For extra info, please go to clearsidebio.com and comply with us on LinkedIn and X.
Cautionary Observe Relating to Ahead-Wanting Statements
Any statements contained on this press launch that don’t describe historic information could represent forward-looking statements as that time period is outlined within the Non-public Securities Litigation Reform Act of 1995. These statements could also be recognized by phrases akin to “consider”, “count on”, “could”, “plan”, “potential”, “will”, and related expressions, and are based mostly on Clearside’s present beliefs and expectations. These forward-looking statements embody statements relating to the medical improvement of CLS-AX, the reporting of outcomes from the ODYSSEY medical trial, the potential advantages of Mr. Gibney becoming a member of the Board of Administrators and the potential advantages of CLS-AX and different product candidates utilizing Clearside’s SCS Microinjector®. These statements contain dangers and uncertainties that would trigger precise outcomes to vary materially from these mirrored in such statements. Dangers and uncertainties that will trigger precise outcomes to vary materially embody uncertainties inherent within the conduct of medical trials, Clearside’s reliance on third events over which it could not at all times have full management and different dangers and uncertainties which might be described in Clearside’s Annual Report on Type 10-Okay for the yr ended December 31, 2023, filed with the U.S. Securities and Alternate Fee (SEC) on March 12, 2024 and Clearside’s different Periodic Reviews filed with the SEC. Any forward-looking statements communicate solely as of the date of this press launch and are based mostly on info obtainable to Clearside as of the date of this launch, and Clearside assumes no obligation to, and doesn’t intend to, replace any forward-looking statements, whether or not because of new info, future occasions or in any other case.
Supply: Clearside Biomedical, Inc.
A photograph accompanying this announcement is offered at https://www.globenewswire.com/NewsRoom/AttachmentNg/1dc9e939-b913-4861-947a-500542b41a20
Investor and Media Contacts: Jenny Kobin Remy Bernarda [email protected] (678) 430-8206
